Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study

BACKGROUND: The aim of the study was to observe the safety and efficacy of anlotinib (ANL) alone or combined with S-1 in the first-line treatment of advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Fifty-four patients with untreated advanced HCC who could not be resected were randomly...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Mafei, Xue, Feng, Xu, Shengyuan, Shi, Jieqiong, Mo, Yunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476909/
https://www.ncbi.nlm.nih.gov/pubmed/37494583
http://dx.doi.org/10.2478/raon-2023-0036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476909/
https://www.ncbi.nlm.nih.gov/pubmed/37494583
http://dx.doi.org/10.2478/raon-2023-0036

Ejemplares similares